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Abstract
Background: Intracranial malignant peripheral nerve sheath tumors are rare entities that carry a poor prognosis. To
date, there are no established therapeutic strategies for these tumors.
Methods: We review the present treatment modalities and present the current therapeutic dilemmas. We perform
a statistical analysis to evaluate the prognostic factors for Overall Survival of these patients. Additionally, we present
our experience with a 64-year-old man with a MPNST of the left cerebellopontine angle.
Results: To our best knowledge, forty three patients with intracranial MPNSTs, including our case, have been
published in the international literature. Our analysis showed gross total resection, radiotherapy and female gender
to be beneficial prognostic factors of survival in the univariate analysis. Gross total resection was recognized as the
only independent predictor of prolonged Overall Survival. In our case, we performed a gross total resection
followed for the first time by stereotactically guided radiotherapy.
Conclusion: Considering the results of the statistical analysis and the known advantages of the stereotaxy, we
suggest aggressive surgery followed by stereotactically guided radiotherapy as therapy of choice.
Background
Malignant Peripheral Nerve Sheath Tumors (MPNST)
usually arise de novo or from a malignant transforma-
tion of a neurofibroma. Rarely MPNSTs may arise from
schwannoma, ganglioneuroma or phaeochromocytoma
[1,2]. Incidence rates of MPNSTs are identified at less
than 1/10
6/year, with the majority of cases located in
the brachial or lumbal plexus. Their intracranial occur-
rence is even more sporadic. To date, no generally
accepted therapeutic strategies or prognostic factors of
intracranial MPNSTs are established.
To our best knowledge, 42 cases of intracranial
MPNSTs have been reported in the literature, 16 of
them concerning the VIIIth nerve [3-13]. We review the
applied therapies and identify prognostic factors of OS
for these tumors.
Furthermore, we present a case of a MPNST of the
VIIIth nerve, and propose a novel therapeutic strategy
consisting of aggressive surgical resection followed by
stereotactically guided radiotherapy.
Methods
Twenty case reports and four retrospective clinical stu-
dies concerning intracranial MPNSTs were identified
using the NCBI PubMed. No limitations regarding the
language or time of publication were imposed on the
search process. Two studies concerned MPNSTs as a
whole, including tumors of the head and neck, without
specifying whether the latter were extracranial or intra-
cranial [14,15]. Thus, they were excluded from our
review analysis. Similarly excluded were the cases of
MPNSTs arising from extracranial trigeminal branches.
Overall survival (OS) was analyzed with the Kaplan-
Meier method. Assessments of potential prognostic fac-
tors were carried out using log-rank tests. The multi-
variate analysis was performed using the Cox Regression
Hazard Models- Backward Stepwise Procedure. P values
≤ 0.05 were regarded significant.
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A total of forty three patients with intracranial MPNSTs,
including our case, were identified. The mean age was 37.6
± 20.3 (3-69) years. A male predominance (30 males,
69.8%) was observed. 63.9% of the MPNSTs arised de novo;
the rest derived from benign tumors. NF1 was present in
17.1% of the patients. Gross total resection (GTR) was
achieved in 42.9% whereas 51.3% and 2.3% of the patients
received postoperative adjuvant radiotherapy (RT) and che-
motherapy, respectively (Table 1-[3-5,7-10,12,13,16-26]).
When administrated, radiotherapy was usually whole brain
radiation with 60 Gy fractioned over 6 weeks.
Table 1 Review of published cases of intracranial MPNSTs
No Age Gender Author, Year [Ref.] Site HRT* NF1 MT* Resection RT Chemo OS Death DM/R*
1 13 M Ducatman, 1984 [17] L CN* VII NR* no NR NR NR no NR NR NR
2 18 M Bruner, 1984 [30] frontal NR no no GTR* no no 66 no R
3 15 M Stefanko, 1986 [21] L parietooccipital NR NR no GTR yes yes 9 yes NR
4 24 F Best, 1987 [31] R CPA*, NR no no IR* no no 4 yes NR
5 54 M Matsumoto,1990 [13] R CPA, CN VIII no no NR IR no no 4 yes R
6 47 F Han, 1992 [32] R CPA no no no IR no no 11 yes NR
7 38 M Maeda, 1993 [33] R CPA, CN VIII no no no IR no no 2 yes NR
8 61 F Singh, 1993 [34] R cerebellum NR NR no GTR yes no 18 yes NR
9 8 F Sharma, 1998 [9] R temporal lobe no no no GTR yes no 17 no NR
10 44 M Comey, 1998 [35] R CPA, CN VII,VIII yes yes yes IR no no 12 yes R
11 69 M Saito,2000 [12] L CPA, CN VIII no NR NR IR no no 3 no NR
12 4 F Tanaka, 2000 [36] R parietooccipital NR no no GTR no no 19 no NR
13 30 F Akimoto, 2000 [37] L CN V1 no no no IR yes no 16 yes R
14 57 F Hanabusa,2001 [10] R CPA, CN VIII yes no yes IR yes no 13 yes R
15 13 F Stark, 2001 [38] L CN V2 no no no GTR yes no 14 yes R
16 36 M Ueda, 2004 [39] R+L CN V no yes no IR yes no 10 yes R
17 43 F Gonzalez,2007 [11] L CPA, CN VIII NR no yes GTR yes no 8 yes M
18 NR M Krayenbühl, 2007 [4] inta- suprasellar yes no yes IR yes no 3 no no
19 62 M Miliaras, 2008 [5] L temporal lobe no no no GTR yes no 13 yes R
20 40 F Chibbaro, 2008 [3] L CN V2 no no no IR yes no 21 no R
21 8 M Chen, 2008 [7] L CN V no no yes GTR no no 8 yes R
22 43 M Chen, 2008 [7] L occipital no yes yes IR yes no 4 yes R
23 3 M Chen, 2008 [7] L CN V, CS* NR no no IR no no 4 yes R
24 35 M Chen, 2008 [7] L CN V, CS NR no no IR no no 2 yes NR
25 46 F Chen, 2008 [7] L CN V, CS NR no no GTR yes no 60 no no
26 62 F Chen, 2008 [7] L CPA, CN VII,VIII NR no no GTR no no 4 yes NR
27 5 M Chen, 2008 [7] R V1,orbita NR no no GTR no no 9 yes NR
28 32 M Scheithauer, 2009 [8] R CPA, CN VIII,IX,X,XI yes yes no IR yes no 5 yes M
29 67 M Scheithauer, 2009 [8] R CPA, CN VIII no no yes IR no no 1 yes NR
30 56 M Scheithauer, 2009 [8] R CPA, CN VIII no no yes IR no no 2 yes R
31 32 M Scheithauer, 2009 [8] L CPA, CN VIII no yes no IR no no 3 yes R
32 26 F Scheithauer, 2009 [8] L CPA, CN VII,VIII no no yes IR yes no NR NR NR
33 5 M Scheithauer, 2009 [8] L CPA, CN VIII no no no NR no no NR NR NR
34 69 M Scheithauer, 2009 [8] R frontal lobe no no no NR no no 4 yes R
35 50 M Scheithauer, 2009 [8] L CN VII no NR yes GTR yes no 17 yes NR
36 26 M Scheithauer, 2009 [8] posterior fossa NR NR NR NR NR no NR NR NR
37 50 M Scheithauer, 2009 [8] L CPA NR NR NR NR NR no 36 yes R
38 30 M Scheithauer, 2009 [8] optic chiasma yes NR yes NR no no 2 yes NR
39 59 M Scheithauer, 2009 [8] L gasserion ganglion NR NR NR NR NR no NR NR NR
40 41 M Scheithauer, 2009 [8] posterior fossa NR no NR NR yes no 5 yes R
41 32 M Scheithauer, 2009 [8] CN X yes yes yes IR yes no NR NR M
42 62 M Ziadi, 2010 [40] L CN V3 no no no GTR yes no 17 no no
43 64 M present study L CPA, CN VIII no no yes GTR yes no 12 no no
*HRT: History of radiation exposure, MT: malignant transformation of a former benign entity (mainly neurofibroma or schwannoma), DM/R: distant metastasis/
recurrence, NR: not reported, GTR: gross total resection, IR: incomplete resection, CN: cranial nerve, CPA: cerebellopontine angle, CS: cavernous sinus.
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was not documented in the majority of the cases, and
could not be evaluated.
In the univariate analysis, female gender (p = 0.048),
GTR (p = 0.004) and RT (p = 0.010) were significant
beneficial factors for OS (Figure 1). Notably, younger
age, malignant transformation of a former benign tumor
and the presence of NF1 did not significantly influence
outcome (p > 0.05) (Table 2).
Some factors of potential influence upon OS, such as
histological grade and tumour size, were not estimated
due to the lack of reported data.
We included the significant factors above in a multi-
variate analysis, using the backward stepwise procedure.
GTR was found to be an independent beneficial prog-
nostic factor for OS (HR = 0.258, CI 95% 0.102-0.653,
p = 0.004) (Table 2).
Illustrative Case
A 64-year-old man presented with progressive headache,
vertigo, nausea, hypogeusia and ataxia commencing 3
weeks prior to admission. A left hearing loss was known
since three decades. A brain MRI approximately 10 years
prior to admission revealed a small tumor localized at the
left cerebellopontine angle. There were no history or
clinical stigmata of Neurofibromatosis types 1 and 2.
Preoperative MRI and CT demonstrate a 3.5*4 cm
measuring well delineated contrast-enhancing lesion in
the left cerebellopontine angle with mass effect (Figure
2A, B). A thoracoabdominal CT as well as MRI of bra-
chial and lumbal plexus performed ulteriorly excluded
other manifestations of the MPNST.
A gross total tumor resection using neuromonitoring of
the motor tract and facial nerve function was achieved.
Postoperatively, a transient facial nerve palsy House-
Brackmann grade III occurred as sole complication.
Histopathological examination revealed a highly cellu-
lar tumor with considerable cytologic atypia. (Figure 3).
Immunohistochemical examinations revealed only focal
immunoreactivity for antibodies against S-100-protein
and p75. Tumors cells were strongly immunopositive
for vimentin and variable immunoreative for CD99 and
Figure 1 Kaplan-Meier survival curves showing the influence
of, A) degree of resection, B) radiotherapy and C) gender upon
Overall Survival.
Table 2 Statistical Analysis
Univariate Analysis*
gender resection RT age** NF1 MT
Log Rank p p p p p p
Overall Survival 0.048 0.004 0.010 0.756 0.132 0.140
Multivariate Analysis ***
Resection (GTR vs IR) p = 0.004 HR = 0.258 CI 95% (0.102-0.653)
Gender (female) p = 0.059 HR = 0.401 CI 95% (0.155-1.037)
*Kaplan-Meier method and Log Rank test
** over or under 37.6 years old (mean age)
***Cox proportional hazards model
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Page 3 of 7Figure 2 Preoperative (A+B) and postoperative (C+D) MRIs: (A+C)Axial T1Wse without and (B+D)with contrast.M R If i n d i n g s :
Enlargement of the left IAC. In non-contrast T1w homogeneous intermediate signal mass in the CPA-IAC cistern on the left with displacement
of the middle cerebellar peduncle and strong enhancement after contrast administration. No intramural cysts and no dural tail. C+D, no residual
tumor is shown.
Figure 3 Histopathological examination revealed a highly cellular tumor with considerable cytologic atypia. The cytomorphological
aspect was dominated by spindle cells with eosinophilic cytoplasm and nuclear enlargement as well as hyperchromasia. Brisk mitotic activity
was present, whereas necrosis was no significant feature of the tumor (bar graph - 200 μm).
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FNCLCC grading system [27].
Four weeks after surgery, the patient underwent frac-
tionated stereotactic and image guided radiotherapy
using single isocentre dose delivery. A total of 60 Gy
was delivered in 30 fractions. The treatment was per-
formed using the Novalis(r) system with micro-multi-
leaf-collimator and ExacTrac(r). The patient was immo-
bilized using a relocatable stereotactic frame with an
aquaplast mask (all components by BrainLAB(r), Ger-
many). Because there was no detectable residual tumour
on post operative MRI (Figure 2C, D), the CTV (clinical
target volume) was defined as the former tumour cavity
which was delineated by fusing the pre- and post-op T1
MRI sequences with contrast enhancement. The safety
margin was set to 2 mm receiving the PTV (planning
target volume) of 19.026 cc, (Figure 4A, B). By using 8
non-coplanar conformal static beams the 90% isodose
encompassing PTV with a conformity index of 1.52. All
delivery parameters were according to the guidelines of
RTOG (Figure 4C, D, E, F).
The radiotherapy was well tolerated without acute
toxicities. Clinical and MRI follow up at 12 months is
without any hints of tumour recurrence.
Discussion
In contrast to their benign counterparts, neurofibromas
or schwannomas, intracranial MPNSTs carry a poor
prognosis with a median OS of 9 months, (range 1 to
66 months, present review). In combined series of intra-
cranial and extracranial MPNSTs, Zou et al report a 5-
year survival rate of 38.7%, whereas Anghileri et al
described a 5-year cause-specific mortality of 39.9%.
When the influence of tumor site is considered, Anghi-
leri reported an increased 5-year mortality of head and
neck MPNSTs of 66.7%, as compared to 48.8% and
27.5% of trunk and extremities MPNSTs, respectively.
The rarity of intracranial MPNSTs hampers the estab-
lishment of evidence based strategies for their optimal
treatment. Thus, the management of the intracranial
MPNSTs should also consider the experience gained
from the treatment of extracranial MPNSTs.
Anghileri et al conducted a study of 205 patients with
MPNSTs, of which 9 cases were head and neck tumors,
and found that GTR, achieved in 62% of the patients,
correlated significantly with longer OS, and inversely
with local recurrence on multivariate analysis [14]. Zou
et al carried out another study of 140 patients with
MPNSTs, including 20 tumours of the head and neck,
Figure 4 A) preoperative MRI (tumor brown, CTV blue, PTV red), B) postoperative MRI (tumor brown, CTV blue, PTV red), C) axial and
D) coronal MRI showing radiation plan with isodose lines, E and F) non-coplanar and conformal arrangement of the static beams.
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inversely related to local recurrence on univariate analy-
sis [15]. The results of the present review verify for
intracranial MPNSTs the statistically significant influ-
ence of GTR upon OS in the univariate and multivariate
analysis. Thus, a main goal in the treatment of the intra-
cranial MPNSTs should be the complete surgical
tumour resection with preservation of neurological func-
tion, whenever applicable.
T h er o l eo fa d j u v a n tr a d i o t h erapy remains controver-
sial. Some studies suggest that radiation may be impli-
cated in the pathogenesis of MPNSTs [8,28]. Foley et al
suggested that ionizing radiation may cause chromoso-
mal injury and induce proliferation as well as cytologic
atypia in Schwann cells, resulting in radiation-induced
MPNSTs [29].In our review series, 41.7% of patients
harbouring a malignant transformation to MPNST
received radiation in their history. Other studies haven’t
shown any positive effects of radiotherapy on patients
outcome[30-32], while the recent literature indicates the
beneficial role of the radiotherapy in local control of dis-
ease after a total or a near total resection of extracranial
MPNSTs [14,33-38]. Anghileri et al found adjuvant
radiotherapy to be significantly related to longer OS on
multivariate analysis, while no correlations with local
recurrence or distant metastases were observed [14].
The radiation dosage administrated in the majority of
the cases was 50 - 60 Gy. Our review revealed the bene-
ficial prognostic significance of adjuvant radiotherapy
for OS in the univariate analysis. However, the multi-
variate analysis failed to show an independent influence
of RT on OS. This could be related to the limited sam-
ple of patients. Considering the above findings and the
highly malignant histological appearance of the tumour,
in our patient we decided for adjuvant radiotherapy
with stereotactic guidance due to its precise dosage
delivery while sparing the adjacent healthy brain tissue.
This strategy provides the possibility to apply an ade-
quate high dose of 60 Gy despite of nearby sensitive risk
structures like the brainstem. Thus, we were able to
take advantages of both stereotactic radiotherapy and
conventional fractionation while minimising the risks of
RT-inducing brain injury like radiation necrosis and
cognitive decline.
The optimal radiation dose has not yet been defined.
We decided for a total dose of 60 Gy balancing the rela-
tively high radiation dose to the highly malignant histo-
logical tumour appearance.
Some authors consider MPNSTs to be chemotherapy-
resistant [28] while others suggest that surgery followed
by combined radiochemotherapy results in improved sur-
vival [39]. Two recent studies of large series of peripheral
MPNSTs failed to show any benefit of chemotherapy
[7,34]. Therefore, in our patient, chemotherapy was
decided to be spared for the case of tumour relapse or
metastatic disease.
In the present patient the MPNST seems to have
resulted from the malignant transformation of a pre-
existing benign schwannoma. 36.1% of the review cases
experience a progression of benign tumor to malig-
nancy, having a worse OS compared to MPNSTs arising
de novo. The latter difference though did not reach sta-
tistic significance (8.46 vs 22.95 months, p = 0.140).
These observations point out the importance of a thor-
ough long-time follow-up of all benign intracranial
schwannomas and neurofibromas that have not been
resected. However, it is not clear whether MRI follow-
up can reliably indicate the exceptional transition of a
schwannoma to a MPNST. Approximately, 25 to 50% of
MPNSTs are associated with NF-1. The overall lifetime
risk of genesis of MPNST in patients with NF-1 is esti-
mated to be from 8 to 13% [14,40]. In the present
review 17.1% of intracranial MPNSTs were related to
NF-1.
It is noteworthy, that the female gender is less likely
to present with intracranial MPNST and that females
harbouring this tumour have a significant longer OS
than men. Further studies are needed to enlighten the
background of these observations.
Conclusion
In conclusion, we propose as therapeutic strategy for
intracranial MPNST consisting of the maximal surgical
resection feasible with preservation of neurological func-
tion, followed by adjuvant stereotactically guided radio-
therapy. This strategy minimises the possible
complications of surgery as well as of brain radiation.
Chemotherapy should probably be spared for relapsed
or metastasized disease.
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